Wadstrom H, et al. - The risk of incident malignant neoplasms in patients with rheumatoid arthritis (RA) treated with biological disease-modifying antirheumatic drugs (bDMARDs) was evaluated in this study. The overall risk of cancer among patients with RA initiating tumor necrosis factor inhibitor (TNFi) as first or second bDMARD, tocilizumab, abatacept, or rituximab does not differ substantially from that of biologic drug-naive, csDMARD-treated patients with RA, although altered risks for specific cancer types, or those with longer latency, cannot be excluded.